SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

The World Cup warning: Riots don’t start in the streets. They start online

“There’s a price where you have to say yes”: CyberArk founder on the $25 billion Palo Alto deal

"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"

“There is no better solution for Zim than the one we created”

Buzz

Most popular

Daily

Weekly

1

"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"

2

Iron Dome and Iron Beam maker Rafael unveils new weapon against the drone threat

3

"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"

4

Echo: “Employees have become very good at identifying performative culture”

5

Unicorn Artlist to cut 200 jobs, 40% of workforce, despite surpassing $300 million ARR

Gilead

6 stories about Gilead

מנכ"לית קומפיוג'ן ד"ר ענת כהן דייג

Compugen shares soar on massive deal with Gilead, worth up to $848 million

19.12.23|Sophie Shulman

The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies

פרופסור זליג אשחר

Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall

16.01.18|Zohar Shahar Levy

Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights

ההכרזה של דולנד טראמפ על ירושלים 2

CTech’s Daily Israeli Tech News Roundup

Backlash against Trump’s Jerusalem declaration has reached Israeli tech. AmTrust is planning a listing on Tel Aviv Stock Exchange. Teva’s stock is up following news of more layoffs.

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich

Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"

Meet Kite Pharma's CEO, the Man Bringing Hope to Hodgkin's Lymphoma Patients

30.08.17|Dror Reich

With two exits worth hundreds of millions of dollars to his name even before selling Kite Pharma for $12 billion dollars, just where will Arie Belldegrun aim next?

Gilead To Buy Kite Pharma for $11.9 Billion

29.08.17|Dror Reich

The drug company is looking to diversify into cell therapy following declining hepatitis c drug sales